These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 6538948)

  • 21. Basic research in substantia nigra and ventral tegmental area: clinical implications.
    Stratta F; Bonci A; Calabresi P; Stefani A; Pisani A; Bernardi G; Mercuri NB
    J Neural Transm Suppl; 1995; 45():47-55. PubMed ID: 8748608
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Functional neuroanatomy of the basal ganglia in Parkinson's disease.
    Wichmann T; DeLong MR
    Adv Neurol; 2003; 91():9-18. PubMed ID: 12442660
    [No Abstract]   [Full Text] [Related]  

  • 23. Peculiarities of L: -DOPA treatment of Parkinson's disease.
    Kostrzewa RM; Nowak P; Kostrzewa JP; Kostrzewa RA; Brus R
    Amino Acids; 2005 Mar; 28(2):157-64. PubMed ID: 15750845
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A critical review of the function of neuromelanin and an attempt to provide a unified theory.
    Nicolaus BJ
    Med Hypotheses; 2005; 65(4):791-6. PubMed ID: 15949901
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oestrogen and nigrostriatal dopaminergic neurodegeneration: animal models and clinical reports of Parkinson's disease.
    Liu B; Dluzen DE
    Clin Exp Pharmacol Physiol; 2007 Jul; 34(7):555-65. PubMed ID: 17581209
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modifications of the iron-neuromelanin system in Parkinson's disease.
    Fasano M; Bergamasco B; Lopiano L
    J Neurochem; 2006 Feb; 96(4):909-16. PubMed ID: 16417570
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson's disease.
    Sasaki M; Shibata E; Tohyama K; Takahashi J; Otsuka K; Tsuchiya K; Takahashi S; Ehara S; Terayama Y; Sakai A
    Neuroreport; 2006 Jul; 17(11):1215-8. PubMed ID: 16837857
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
    Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H
    J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The possible role of iron in the etiopathology of Parkinson's disease.
    Youdim MB; Ben-Shachar D; Riederer P
    Mov Disord; 1993; 8(1):1-12. PubMed ID: 8419792
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Parkinson's disease: unanswered questions.
    Calne DB; Kebabian JK
    J Neural Transm Suppl; 1980; (16):1-5. PubMed ID: 6933216
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serotonin modulation of the basal ganglia circuitry: therapeutic implication for Parkinson's disease and other motor disorders.
    Di Matteo V; Pierucci M; Esposito E; Crescimanno G; Benigno A; Di Giovanni G
    Prog Brain Res; 2008; 172():423-63. PubMed ID: 18772045
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Die Pathoklise [Parkinson's disease].
    Stern G
    J Neural Transm Suppl; 1993; 40():93-9. PubMed ID: 8294903
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia.
    Sian J; Dexter DT; Lees AJ; Daniel S; Agid Y; Javoy-Agid F; Jenner P; Marsden CD
    Ann Neurol; 1994 Sep; 36(3):348-55. PubMed ID: 8080242
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification and kainic acid-induced up-regulation of low-affinity p75 neurotrophin receptor (p75NTR) in the nigral dopamine neurons of adult rats.
    Wang YQ; Bian GL; Bai Y; Cao R; Chen LW
    Neurochem Int; 2008 Sep; 53(3-4):56-62. PubMed ID: 18639597
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanisms of MPTP toxicity and their implications for therapy of Parkinson's disease.
    Watanabe Y; Himeda T; Araki T
    Med Sci Monit; 2005 Jan; 11(1):RA17-23. PubMed ID: 15614202
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of age and gender on cytokine expression in a murine model of Parkinson's disease.
    Ciesielska A; Joniec I; Kurkowska-Jastrzebska I; Przybyłkowski A; Gromadzka G; Członkowska A; Członkowski A
    Neuroimmunomodulation; 2007; 14(5):255-65. PubMed ID: 18196934
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gender differences in neurotoxicity of the nigrostriatal dopaminergic system: implications for Parkinson's disease.
    Dluzen DE; McDermott JL
    J Gend Specif Med; 2000; 3(6):36-42. PubMed ID: 11253381
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Current views on the mechanisms of dopaminergic neuron death of the nigrostriatal system in Parkinson's disease].
    Bertrand E; Lechowicz W; Szpak GM; Dymecki J
    Neurol Neurochir Pol; 1997; 31(2):295-302. PubMed ID: 9380259
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The development of animal models for studies in Parkinson's disease.
    Poirier LJ
    Contemp Neurol Ser; 1971; 8():83-117. PubMed ID: 5005690
    [No Abstract]   [Full Text] [Related]  

  • 40. On the origin and significance of neuromelanin.
    Graham DG
    Arch Pathol Lab Med; 1979 Jul; 103(7):359-62. PubMed ID: 582279
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.